Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes.

Abstract: The present invention provides a tomaymycin biosynthetic gene cluster of Streptomyces species FH6421, and its use for producing 11-de-O-methyltomaymycin.

Abstract: The present invention refers to the gene cluster and genes comprised by the gene cluster which are involved in the biosynthesis of griselimycin and methylgriselimycin and to the use of the gene cluster, genes comprised thereby and proteins encoded thereby for the production of antibiotic agents.

Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoaguability or fibrotic changes.

Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The disclosure relates to a compound of the formula (I) wherein R1 is H, C(O)—(C1-C6)alkyl or C(O)—O—(C1-C6)alkyl; R2 is OH, NH2, NH—(C1-C6)alkyl, NH—(C1-C4)alkylene-phenyl or NH—(C1-C4)alkylene-pyridyl; R3 and R4 are independently of each other H or OH, or R3 and R4 together are ?O; and m and n are independently of one another 0, 1 or 2; in any stereochemical form, or a mixture of any stereochemical forms in any ratio, or a physiologically acceptable salt thereof, obtainable from Actinomadura namibiensis (DSM 6313), and its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.

Abstract: The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The invention relates to compounds of the formula (I) which are inhibitors of activated thrombin-activable fibrinolysis inhibitor. The compounds of the formula I are suitable for producing medicaments for prophylaxis, secondary prevention and treatment of one or more disorders associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The invention refers to so-called Labyrinthopeptin derivatives of the formula (I) wherein {A}, {B}, {C}, R1-R6, m and n are as defined herein, obtainable from microorganism strain Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, a pharmaceutical composition comprising it, prepro-Labyrinthopeptin, pro-Labyrinthopeptin, and DNA coding for prepro-Labyrinthopeptin and pro-Labyrinthopeptin.

Abstract: The invention relates to compounds of the formula I as defined herein, which are inhibitors of activated thrombin-activatable fibrinolysis inhibitor. The compounds of the formula I are suitable for manufacturing medicaments for the prophylaxis, secondary prevention and therapy of one or more disorders which are associated with thromboses, embolisms, hypercoagulability or fibrotic changes.

Abstract: The disclosure relates to a compound of the formula (I) wherein m and n are independently of one another 0, 1 or 2, obtainable from Actinomadura namibiensis (DSM 6313), its use for the treatment of bacterial infections, viral infections and/or pain, and pharmaceutical composition comprising it.

Abstract: The present invention relates to novel hydroxyphenylundecane derivatives of the formula (I), a method for the preparation of said compounds by cultivation of the fungus Cryphonectria parasitica, DSM 14453, and their use as pharmaceuticals, i.e. for the treatment of Alzheimer's Disease, Parkinson's Disease, Huntington's Diseases, stroke, psychosis and/or depressions.

Abstract: The present invention relates to novel active compounds named Citrullimycines, which are obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309), and to their pharmaceutically acceptable salts and derivatives. The present invention further relates to a process for the production of the Citrullimycines, to the microorganism Streptomycetes sp. ST 101396 (DSM 13309), to the use of the Citrullimycines and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, for example as inhibitors of the neurotensin receptor, and to pharmaceutical compositions comprising Citrullimycines or a pharmaceutically acceptable salt or derivative thereof.

Abstract: The present invention relates to novel caloporoside derivatives and method of their use. The caloporoside derivatives may be formed by fermentation of microorganisms, such as Gloeoporus dichrous (Fr.: Fr.) Bres. ST001714 (DSM 13784). The invention also relates to use to a process for preparing caloporoside derivatives, drugs comprising such compounds, and methods of their use. The invention further relates to the microorganism Gloeoporus dichrous Bres. ST001714 (DSM 13784).